Gene Regulatory Laboratory, School of Medicine, Tsinghua University, 100084 Beijing, China.
Institute for Human Genetics and Department of Neurology, University of California, San Francisco, CA 94143.
Proc Natl Acad Sci U S A. 2018 May 1;115(18):4719-4724. doi: 10.1073/pnas.1800677115. Epub 2018 Apr 16.
CRISPR/Cas9-based transcriptional activation (CRISPRa) has recently emerged as a powerful and scalable technique for systematic overexpression genetic analysis in We present flySAM, a potent tool for in vivo CRISPRa, which offers major improvements over existing strategies in terms of effectiveness, scalability, and ease of use. flySAM outperforms existing in vivo CRISPRa strategies and approximates phenotypes obtained using traditional Gal4-UAS overexpression. Moreover, because flySAM typically requires only a single sgRNA, it dramatically improves scalability. We use flySAM to demonstrate multiplexed CRISPRa, which has not been previously shown in vivo. In addition, we have simplified the experimental use of flySAM by creating a single vector encoding both the UAS:Cas9-activator and the sgRNA, allowing for inducible CRISPRa in a single genetic cross. flySAM will replace previous CRISPRa strategies as the basis of our growing genome-wide transgenic overexpression resource, TRiP-OE.
基于 CRISPR/Cas9 的转录激活(CRISPRa)最近成为一种强大且可扩展的技术,可用于系统地上调遗传分析。我们提出了 flySAM,这是一种用于体内 CRISPRa 的有效工具,与现有策略相比,在有效性、可扩展性和易用性方面有了重大改进。flySAM 优于现有的体内 CRISPRa 策略,并接近使用传统 Gal4-UAS 过表达获得的表型。此外,由于 flySAM 通常只需要一个 sgRNA,因此它极大地提高了可扩展性。我们使用 flySAM 来展示以前在体内未显示的多路复用 CRISPRa。此外,我们通过创建一个同时编码 UAS:Cas9-激活子和 sgRNA 的单个载体,简化了 flySAM 的实验使用,从而可以在单个遗传杂交中进行诱导型 CRISPRa。flySAM 将取代以前的 CRISPRa 策略,成为我们不断增长的全基因组转基因过表达资源 TRiP-OE 的基础。